The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | First-in-human study of talquetamab: a GPRC5D-CD3 bispecific antibody for R/R MM
Amrita Krishnan, MD, City of Hope National Medical Center, Duarte, CA, discusses the results of an ongoing Phase I study (NCT03399799) of talquetamab for relapsed/refractory multiple myeloma (MM). Since expression of GPRC5D is high in primary MM cells and limited elsewhere, targeting it with talquetamab, a GPRC5D-CD3 bispecific antibody, can induce T-cell mediated cytotoxicity of MM cells. Subcutaneous (SC) and intravenous (IV) administration is being investigated in the process of establishing a recommended Phase II dose. Treatment at higher doses is ongoing, and a recommended Phase II dose will be presented. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Transcript
Talquetamab is a bispecific dual body T-cell engager targeting GPRC5D, which is the G-protein receptor that has some, it is expressed primarily in plasma cells, but it’s actually also expressed in hair follicles. And this is a first-in-class dual body antibody that’s biding to GPRC and to CD3. And similar to teclistamab we’ve seen that it redirects T-cells to the GPRC expressing myeloma cells and mediate cell killing...
Talquetamab is a bispecific dual body T-cell engager targeting GPRC5D, which is the G-protein receptor that has some, it is expressed primarily in plasma cells, but it’s actually also expressed in hair follicles. And this is a first-in-class dual body antibody that’s biding to GPRC and to CD3. And similar to teclistamab we’ve seen that it redirects T-cells to the GPRC expressing myeloma cells and mediate cell killing.
The trial that my colleague Dr Chari is going to present is the Phase I dose escalation trial of this agent in patients with relapsed/refractory myeloma. We looked at both IV and sub-cu dosing, and we’ll be presenting on a total of 157 patients with the primary emphasis being on the sub-cu dosing group of patients. Again, these are very heavily treated patients in the 2% with triple class exposed and refractory and 33% with penta-drug refractory. 95% had had prior daratumumab.
Side effects, again, in keeping with this class of agents, cytokine release syndrome in about 54% of patients, the majority of it were grade one and grade two. Hematologic toxicity in about 30 to 50% of patients. Anemia, neutropenia, and thrombocytopenia. Interestingly and unique for this agent, again speaking to where it is expressed, we also saw nail disorders in 13% of patients in the Phase I portion, and up to 20% in the expansion cohort. At the highest dose of 800 micrograms, we had a response rate of 73%. The overall response rate that we’re reporting out at the RP2D dose it was 69%. And again, this is still very early follow-up on these patients. Median follow-up at the RP2D dose is only 3.7 months. So again, durability of those responses remain to be seen.
Read more...
